Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis. Kvartskhava T, Freudenstein D, Sarmiento N, Angstwurm K, et al. J Neurol Sci 2025;475:123577.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kvartskhava T, Freudenstein D, Sarmiento N, Angstwurm K, et al. Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis. J Neurol Sci 2025;475:123577.
PMID: 40505352